Andrew Allen

Dr. Allen is a co-founder of Gritstone Oncology, Inc. (NASDAQ: GRTS), and has served as its President, Chief Executive Officer, and board member since its inception in August 2015. Prior to Gritstone, in April 2009, Dr. Allen co-founded Clovis Oncology, Inc., or Clovis, a public pharmaceutical development company, and served as its executive vice president of clinical and preclinical development and a chief medical officer from April 2009 to July 2015. Prior to that, he was a chief medical officer at Pharmion Corporation from 2006 to 2008 (acquired by Celgene for $2.9B). Previously, Dr. Allen served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories and worked at McKinsey & Company, where he advised life science companies on strategic issues. He currently serves on the board of directors of Epizyme, Inc., Sierra Oncology, Inc., both public biopharmaceutical companies, and Revitope Oncology, Inc, a private biotechnology company. Dr. Allen previously served on the board of directors of Cell Design Labs, a private biotechnology company, from November 2015 until its acquisition by Gilead Sciences, Inc. in December 2017. Dr. Allen qualified in medicine at Oxford University and received a Ph.D. in immunology from the Imperial College of Science, Technology, and Medicine in London.